Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Issued: 2015-2025

Historic Shares Issued for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $5.8 million.

  • Syndax Pharmaceuticals' Shares Issued rose 126.80% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 100.38%. This contributed to the annual value of $8.0 million for FY2024, which is 56.01% up from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Shares Issued is $5.8 million, which was up 1,142.09% from $468,000 recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Shares Issued ranged from a high of $162.0 million in Q4 2022 and a low of -$69.9 million during Q2 2021.
  • Its 3-year average for Shares Issued is $1.8 million, with a median of $1.6 million in 2023.
  • Data for Syndax Pharmaceuticals' Shares Issued shows a peak YoY increase of 22,089.35% (in 2021) and a maximum YoY decrease of 6,679.00% (in 2021) over the last 5 years.
  • Syndax Pharmaceuticals' Shares Issued (Quarterly) stood at $81.2 million in 2021, then soared by 99.51% to $162.0 million in 2022, then crashed by 99.93% to $112,000 in 2023, then soared by 2,702.68% to $3.1 million in 2024, then skyrocketed by 126.80% to $5.8 million in 2025.
  • Its Shares Issued was $5.8 million in Q3 2025, compared to $468,000 in Q2 2025 and $545,000 in Q1 2025.